Emergent BioSolutions (NYSE: EBS) reported Q2 EPS of ($1.06), $0.43 worse than the analyst estimate of ($0.63). Revenue for the quarter came in at $337.9 million versus the consensus estimate of $217.03 million.

For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.